The Cancer

Don't Miss

Childhood Most cancers Survivors Face Lengthy-Time period Meningioma Danger

Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...

Professional Discusses FDA Approval of Chemo-Free Possibility for EGFR-Mutated Lung Most cancers

The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...

FDA Clears Protocol Replace for Tasquinimod in Myelofibrosis Trial

Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...

Vital Information

Facts

Latest Articles

Dr. Choudry and Dr. Durant on questions raised by pathogenic analysis in genitourinary cancers

On this video, Mouneeb Choudry, MD, and Adri Durant, MD, focus on questions that come up from the Journal of Urology examine “Germline...

Too Many Breast Most cancers Survivors Miss Out on Genetic Screening – Citizentribune

Too Many Breast Most cancers Survivors Miss Out on Genetic Screening  Citizentribune

Therapeutic Choices for NSCLC with Uncommon Mutations – Most cancers Community

Therapeutic Choices for NSCLC with Uncommon Mutations  Most cancers Community

NICE backs first ‘take at house’ prostate most cancers tablet

Hundreds of males within the UK with superior hormone-sensitive prostate most cancers might quickly be eligible for an oral remedy – Accord Healthcare's...

Hot Topics